UCB seals marketing EU deal for anaphylaxis treatment

UCB has announced it has agreed to market Twinject, an epinephrine injection system, for the treatment of anaphylactic shock in patients throughout Europe.

The Belgian pharmaceutical has appointed Verus as a marketing partner for the drug, which includes a delivery system which allows two doses of epinephrine in 0.3mg and 0.15mg forms.

Under the terms of the agreement, UCB will make an upfront payment to Verus, with milestone, sales and royalty payments to follow.

Furthermore, the UCB has gained the option to commercialise the Twinject product line outside Europe – excluding the US and Canada – as well as acquiring the right to market certain next-generation Twinject products in development.

UCB said would “move toward” beginning regulatory approval in Europe for its newly-acquired Twinject products.

Robert W Keith, president and chief executive officer of Verus, remarked: “There are significant unmet medical needs for those individuals at risk for anaphylaxis and, unfortunately, a dual-dose treatment option is not available in Europe today.”

“As a result, we are very pleased to be partnering with UCB, a company with a premier allergy franchise and significant commercial capabilities, to bring Twinject to European patients at risk for this life-threatening condition,” he added.

UCB’s allergy treatments include over-the-counter treatments like Zirtek, as well as Xyzal and Tussionex. In addition, the company operates the UCB Institute of Allergy, which aims to improve communication over allergy treatment and further research into allergic diseases.

© Adfero Ltd